Altre lingue Elicio Therapeutics, Inc.

Azioni

ELTX

US28657F1030

Prezzo di chiusura Nasdaq Altri mercati azionari 00:00:00 05/07/2024			Variaz. 5gg	Var. 1 gen.
3,67 ^USD	-0,27%		-46,73%	-56,00%

28/06	Le azioni di Elicio Therapeutics crollano dopo la quotazione di un'offerta pubblica sottoscritta da 11,5 milioni di dollari	MT
28/06	Wall Street si appresta ad aprire in rialzo venerdì, grazie ai dati chiave sull'inflazione che indicano un raffreddamento della stessa	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell Microcap Growth Index	01/07
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell 3000E Index	01/07
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell Microcap Index	01/07
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell 3000E Growth Index	01/07
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell Microcap Value Index	01/07
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell 3000E Value Index	01/07
Elicio Therapeutics Stock Falls After $11.5 Million Underwritten Public Offering Priced	28/06
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	28/06
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering	28/06
Sector Update: Health Care Stocks Higher Pre-Bell Friday	28/06
Investors Await Key Inflation Data as US Futures Trend Higher Pre-Bell	28/06
Top Premarket Decliners	28/06
Elicio Therapeutics Launches Public Offering; Shares Tumble After-Hours	27/06
Elicio Therapeutics Announces Proposed Public Offering	27/06
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P	27/06
Elicio Therapeutics, Inc. Announces Preliminary Disease-Free Survival Analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P	27/06
Elicio Therapeutics Reports Inducement Grants	18/06
Elicio Therapeutics : AMPLIFY 7P, a first in human safety and efficacy trial of adjuvant mKRAS specific lymph node targeted Amphiphile ELI 002 7P vaccine in minimal residual disease positive pancreatic and colorectal cancer patients (ASCO 2024 – Scientific Poster)	01/06
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting	23/05
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting	23/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Elicio Therapeutics, Inc.

Azioni

ELTX

US28657F1030

Altre lingue

Filtri